IL-22Ra2 Levels Remain Elevated in People with Cystic Fibrosis despite Modulator Therapy.

The article highlights ongoing challenges in managing cystic fibrosis (CF) in patients despite advancements in modulator therapies. Topics include the persistence of chronic bacterial infections within the lungs and airways that remain a hallmark of CF, the limitations of current therapies in fully controlling infection and inflammation, and the need for further research to enhance treatment efficacy for patients who do not respond optimally to modulators.